» Articles » PMID: 15699087

A Systematic Review Describing the Prognosis of Chronic Fatigue Syndrome

Overview
Date 2005 Feb 9
PMID 15699087
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To perform a systematic review of studies describing the prognosis of chronic fatigue (CF) and chronic fatigue syndrome (CFS) and to identify occupational outcomes from such studies.

Method: A literature search was used to identify all studies describing the clinical follow-up of patients following a diagnosis of CF or CFS. The prognosis is described in terms of the proportion of individuals improved during the period of follow-up. Return to work, other medical illnesses and death as outcomes are also considered, as are variables which may influence prognosis.

Results: Twenty-eight articles met the inclusion criteria and, for the 14 studies of subjects meeting operational criteria for CFS, the median full recovery rate was 5% (range 0-31%) and the median proportion of patients who improved during follow-up was 39.5% (range 8-63%). Less fatigue severity at baseline, a sense of control over symptoms and not attributing illness to a physical cause were all associated with a good outcome. Return to work at follow-up ranged from 8 to 30% in the three studies that considered this outcome.

Conclusions: Full recovery from untreated CFS is rare. The prognosis for an improvement in symptoms is less gloomy. This review looks at the course of CF/CFS without systematic intervention. However, there is increasing evidence for the effectiveness of cognitive behavioural and graded exercise therapies. Medical retirement should be postponed until a trial of such treatment has been given.

Citing Articles

Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT.

Crawley E, Anderson E, Cochrane M, Shirkey B, Parslow R, Hollingworth W Health Technol Assess. 2024; 28(70):1-134.

PMID: 39485730 PMC: 11590115. DOI: 10.3310/VLRW6701.


Exploring the role of galectin-9 and artemin as biomarkers in long COVID with chronic fatigue syndrome: links to inflammation and cognitive function.

Elahi S, Rezaeifar M, Osman M, Shahbaz S Front Immunol. 2024; 15:1443363.

PMID: 39386210 PMC: 11461188. DOI: 10.3389/fimmu.2024.1443363.


Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Rekeland I, Sorland K, Neteland L, Fossa A, Alme K, Risa K PLoS One. 2024; 19(7):e0307484.

PMID: 39042627 PMC: 11265720. DOI: 10.1371/journal.pone.0307484.


BioMapAI: Artificial Intelligence Multi-Omics Modeling of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.

Xiong R, Fleming E, Aiken E, Caldwell R, Vernon S, Kozhaya L bioRxiv. 2024; .

PMID: 38979186 PMC: 11230215. DOI: 10.1101/2024.06.24.600378.


New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.

Carvajal J, Garcia-Castillo V, Cuellar S, Campillay-Veliz C, Salazar-Ardiles C, Avellaneda A Front Immunol. 2024; 15:1363572.

PMID: 38911850 PMC: 11190347. DOI: 10.3389/fimmu.2024.1363572.